|
|
|
| Application of serum amyloid A combined with tumor markers in the diagnosis and treatment of senile lung cancer |
| BU Xiaomin1 XIA Liang2 LI Liwen2 |
1.Department of Clinical Laboratory, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Zhejiang Province, Hangzhou 310022, China;
2.Department of Neurosurgery, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Zhejiang Province, Hangzhou 310022, China |
|
|
|
Abstract Objective To investigate the value of serum amyloid A (SAA) combined with neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)125 in the diagnosis of senile lung cancer. Methods A total of 210 senile patients with lung cancer (including 119 cases of adenocarcinoma, 66 cases of squamous cell carcinoma, 25 cases of small cell carcinoma ) in Cancer Hospital of the University of Chinese Academy of Sciences from January to December 2018 were selected as lung cancer group and 120 senile patients with lung benign diseases as benign control group，and 50 healthy senile persons during the same period were selected as health control group. The levels of serum SAA, NSE，CEA and CA125 were detected, and receiver operating characteristic curve was applied to analyze the diagnostic value of each index in senile patients with lung cancer. Results The levels of SAA, NSE, CEA and CA125 in lung cancer group were higher than those in the benign control group and healthy control group (all P ＜ 0.05). SAA level in adenocarcinoma was lower than that in squamous cell carcinoma and small cell carcinoma, and NSE level in adenocarcinoma and squamous cell carcinoma were lower than those in small cell carcinoma (all P < 0.05), while there were no significant differences in CEA and CA125 levels among the three groups (P > 0.05). SAA, NSE, CEA and CA125 levels of Ⅲ-Ⅳ period patients were higher than those of Ⅰ-Ⅱ period patients, and SAA, NSE, CEA and CA125 levels of patients with distant metastasis were higher than those of patients without distant metastasis (all P < 0.01). The AUC, sensitivity and specificity of SAA in the diagnosis of senile lung cancer were 0.569, 67.14% and 46.67% respectively; the AUC, sensitivity and specificity of NSE in the diagnosis of senile lung cancer were 0.694, 55.71% and 73.33% respectively; the AUC, sensitivity and specificity of CEA in the diagnosis of senile lung cancer were 0.583, 30.48% and 95.00% respectively; the AUC, sensitivity and specificity of CA125 in the diagnosis of senile lung cancer were 0.649, 42.38% and 85.00% respectively; and the AUC, sensitivity and specificity of combined detection in the diagnosis of senile lung cancer were 0.745, 47.62% and 96.67% respectively. Conclusion Combined detection of SAA, NSE, CEA and CA125 can significantly improve the diagnostic efficiency of elderly lung cancer.
|
|
|
|
|
|
[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[2] 杨希萍.血清肿瘤标记物、相关抗原及联合检测在肺癌患者诊断中的意义[J].实用癌症杂志，2017，32（8）：1279-1282.
[3] 曹琳，宋晓文，任金来，等.血清淀粉样蛋白A的研究进展[J].安徽医药，2019，23（2）：221-224.
[4] 李保林，王猛，于丹军，等.血清淀粉样蛋白A与肿瘤相关性研究进展[J].检验医学与临床，2018，15（22）：143-146.
[5] 陈万青，李贺，孙可欣，等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志，2018，40（1）：5-13.
[6] 罗桑艳.血清神经元特异性烯醇化酶、细胞角蛋白19片段、癌胚抗原检测在肺癌诊断中的价值[J].现代实用医学，2017，29（12）：1590-1592.
[7] 曾汉华，温雅.多标志物联合检测肺癌及其对肺癌病理类型预测的价值分析[J].中国医药科学，2020，10（2）：19-22.
[8] 余博，吕治平，何进喜.血清肿瘤标志物水平在晚期非小细胞肺癌靶向治疗效果评价中的应用[J].中国现代医生，2018，56（21）：72-74.
[9] 王莉，赵莹，张辉，等.多种血清肿瘤标志物联合检测诊断非小细胞肺癌的价值分析[J].河北医药，2019，41（17）：2594-2597.
[10] 王颖轶，陈书长.老年肺癌早期诊断中多项肿瘤标记物的联合应用[J].中国肿瘤临床与康复，2014，21（3）：257-260.
[11] 杨渭临，田应选，南岩东，等.老年肺癌早期诊断血清肿瘤标志物及其组合的Logistic模型筛选研究[J].现代肿瘤医学，2010，18（11）：2139-2142.
[12] 翟志强.血清CYFRA21-1、CEA联合MMP-1和SAA在非小细胞肺癌检测中的价值分析[J].标记免疫分析与临床，2018，25（8）：1159-1163，1195.
[13] Roudi R，Madjd Z，Korourian A，et al. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer [J]. Cancer Biomark，2014，14（6）：457-467.
[14] 段昕，贾春芳，段敏，等.CA199、NSE、CYFRA21-1、TPS和CEA联合检测在肺癌诊断中的应用价值[J].中国实验诊断学，2014，18（2）：231-234.
[15] Li J，Chen P，Mao CM，et al. Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer [J]. Asia-Pac J Clin Onco，2014，10（2）：141-148.
[16] Wang B，He YJ，Tian YX，et al. Clinical utility of haptoglobin in combination with CEA，NSE and CYFRA21-1 for diagnosis of lung cancer [J]. Asian Pac J Cancer Prev，2014，15（22）：9611-9614.
[17] 李攀，阳剑，曹辉彩.血清淀粉样蛋白A和C-反应蛋白对儿童支原体肺炎的诊断价值[J].中国医药导报，2017， 14（25）：134-137.
[18] 王胜，束新华，叶珍，等.血清淀粉样蛋白A在肺癌诊断中的应用[J].中华检验医学杂志，2016，39（3）：220-224.
[19] 林风武，梁飞海，张川，等.血清淀粉样蛋白A对肺癌的诊断意义[J].中国实验诊断学，2016，20（9）：1506-1507.
[20] Biaoxue R，Hua L，Wenlong G，et al. Increased serum amyloid A as potential diagnostic marker for lung cancer：a meta-analysis based on nine studies [J]. BMC Cancer，2016，16（1）：836.
[21] 廖贵莉，张月霞，许秀军，等.血清淀粉样蛋白A联合肿瘤标志物检测在肺癌中的应用[J].国际检验医学杂志，2016，37（24）：3500-3501.
[22] 王明，夏彦民，王文辰，等.血清ProGRP、Cyfra21-1、SAA、CEA在肺癌中的诊断价值[J].检验医学与临床，2017，14（18）：2686-2688. |
|
|
|
